Negative Symptoms Associated with Psychotic Disorders Induced by Narcotic Substances
Open Access
- 3 August 2026
- journal article
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (3) , 20-30
Abstract
Background : the characteristics of negative symptoms of drug-induced psychotic disorders (PD) caused by narcotic substances (NS) remain incompletely understood, which impedes the differential diagnosis with schizophrenia . The aim was to compare the presentation and severity of negative symptoms after psychotic disorders induced by the narcotic substances and schizophrenic psychosis in determining their significance for differential diagnosis. Patients and Methods : an observational cross-sectional study was conducted involving 141 patients, who were divided into 4 groups: 1) 21 patients with PD caused by natural cannabinoids; 2) 56 patients with PD induced by the synthetic cathinones; 3) 29 patients with PD induced by the several NS; 4) 35 patients with schizophrenia. Negative symptoms were assessed using the CAINS clinical interview, adapted for the Russian-speaking population. Statistical analysis included nonparametric methods of comparing multiple groups and subsequent post hoc analysis. Results : patients with schizophrenia had statistically significantly more pronounced negative symptoms on the emotional expressiveness subscale compared to all groups of narcotic-induced psychoses (p < 0.001). According to the CAINS total score, patients with schizophrenia differed signficantly from the synthetic cathinones-induced PD and several narcotic-induced PD groups (p < 0.001), but not from the natural cannabinoids-induced PD group (p = 0.47). Patients with natural cannabinoids-induced PD demonstrated the most pronounced negative symptoms among all groups of narcotics-induced psychoses, which were similar to schizophrenia in all areas, except emotional expressiveness. The synthetic cathinones-indused PD and several narcotic-induced PD groups were characterized by significantly less pronounced anticipatory negative symptoms and better motivation in the social, professional, and recreational spheres than patients with schizophrenia. Conclusion : significant differences in the profile of negative symptoms between psychotic disorders induced by different NS were identified. PD induced by natural cannabinoids were the closest ones to schizophrenia in the severity of negative symptoms, which is clinically significant for differential diagnosis and planning rehabilitation measures.Keywords
This publication has 13 references indexed in Scilit:
- Results of a Multicenter Clinical Study on Adaptation and Validation of the Russian Version of the Clinical Assessment Interview for Negative Symptoms (CAINS)V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY, 2024
- Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2024
- Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individualseClinicalMedicine, 2023
- Analysis of Symptoms, Approaches to Therapy and Outcomes of Synthetic Cathinone-Induced Delirium: Systematic ReviewNauka Molodykh (Eruditio Juvenium), 2023
- The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challengesThe British Journal of Psychiatry, 2023
- Substance-induced or substance-associated primary psychoses? Continuing the discussion. A response to I.А. Fedotov, et alI.P. Pavlov Russian Medical Biological Herald, 2021
- Substance-induced psychosis and schizophrenia: the interaction pointI.P. Pavlov Russian Medical Biological Herald, 2020
- A Comprehensive Examination of the Links between Cannabis Use and MotivationSubstance Use & Misuse, 2020
- Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and TreatmentNeuropsychiatric Disease and Treatment, 2020
- Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortiumPsychological Medicine, 2017